Content Hub

+

What are the learnings from the one-year VANTAGE TAVI outcomes in low/intermediate-risk patients?

What can the 1-year VANTAGE data tell us about the future of TAVI in lower-risk patients? Join B. Gonska, H. Dreger, and C. Saint Etienne as they review the latest outcomes, share expert perspectives, and discuss the implications for patient management and clinical decision-making.

LEARN MORE:

Navitor™ TAVI Webinar 2026 TAVI SUMMIT 2026

MAT-2678890 v1.0

TRENDING TOPICS

Valvular Heart Disease Guidelines at a Glance

Explore the Latest VHD Guideline Updates for Mitral and Tricuspid Regurgitation

Immediate Relief. Durable Benefits

MitraClip™ TEER Delivers Durable MR Reduction and Long-Term Patient Benefits

Reduced HF Hospitalisation. Improved Quality of Life

MitraClip™ TEER Reduces HF Hospitalisations and Improves Patient Outcomes

Der Inhalt dieser Website richtet sich an medizinisches Fachpersonal in der EMEA mit entsprechender Produktregistrierung durch die Gesundheitsbehörde, mit Ausnahme derjenigen, die in Frankreich praktizieren, da einige der Inhalte nicht mit dem französischen Werbegesetz N°2011-2012 vom 29. Dezember 2011, Artikel 34, übereinstimmen. Klicken Sie auf OK, um zu bestätigen, dass Sie Angehöriger eines Gesundheitsberufs sind, um fortzufahren.

OK ablehnen

What are the learnings from the one-year VANTAGE TAVI outcomes in low/intermediate-risk patients?

Related Videos

TRENDING TOPICS

Valvular Heart Disease Guidelines at a Glance

Immediate Relief. Durable Benefits

Reduced HF Hospitalisation. Improved Quality of Life

CONNEXT

ESC 2026 | Live echocardiography

ESC 2026 Symposium

ESC 2026 | Cardiac imaging in aortic stenosis

ESC 2026 | Aortic stenosis CT assessment

CONNEXT

Procedural tip & tricks with Navitor across all valve sizes

Transcatheter Aortic Valves Implant

Transcatheter tricuspid valve repair: Cases, tips and tricks

M-TEER: Best treatment strategies for FMR AND DMR